RecruitingNCT04887792
Acetazolamide or placebo added to usual care for resistant schizophrenia
About this title
Read the official source — NCT04887792Medication studyAges 18–55United States + India
Understand this study
Who could participate?
This study is for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria apply.
- Listed locations
- Pittsburgh and 1 more locationSee all locations and recruitment
- Study phase
- Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: February 1, 2022
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 60
- Sponsor
- Vishwajit Nimgaonkar, MD PhD
- Sponsor type
- Individual investigator
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- United States, India
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT04887792
- Official title
Show the full official title
A Randomized Controlled Trial of Acetazolamide for Patients With Treatment Resistant Schizophrenia
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Pittsburgh, United States · Bangalore, India
Questions about this study
Who is behind this study?
The study sponsor is Vishwajit Nimgaonkar, MD PhD.
Does this study involve medication?
Yes. The study involves medication, including Acetazolamide and Placebo.
Who can participate?
This study is for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
